Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma
Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.